Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

NovaBay: Phase II Topline Results for Auriclosene in UCBE are Very Encouraging (NBY, $1.52)

Investment Overview
I first recommended NovaBay (NBY) as a small company that fit my asymmetric investment strategy in an initiation report…
Read more…

NovaBay: Data from Phase II Trial of Auriclosene in Urinary Catheter Blockage and Encrustation is Imminent (NBY, $1.40)

Company Overview and Purpose of the Report
NovaBay (NBY) will be reporting the results of three Phase II clinical trials involving…
Read more…